Notice of Intent to Sole Source - Abbott Laboratories Inc. - Fort Jackson, SC

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

PANHCA26P0000031152

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details
Set Aside

None

Place of Performance

Columbia, South Carolina, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Special Notice indicating its intent to execute a sole source, out-of-scope bilateral modification to an existing Firm-Fixed-Price, commercial Cost-Per-Reportable-Result (CPRR) contract (W91YTZ25C0003) with Abbott Laboratories, Inc. This procurement action is specifically in support of the Moncrief Army Health Clinic located in Columbia, South Carolina. The primary purpose of this contract modification is to increase the estimated quantities and overall ceiling funding for Option Years 1 through 4. The scope of the modification encompasses the continued provision of Chemistry/Immunochemistry analyzers, along with associated reagents, consumables, calibration materials, and control materials. These supplies are critical to supporting the diagnostic and clinical testing capabilities of the Moncrief Army Health Clinic, thereby directly contributing to the mission readiness and healthcare delivery objectives of both the Defense Health Agency and the Department of the Army. This notice is issued in accordance with the Revolutionary FAR Overhaul (RFO) Federal Acquisition Regulation (FAR) Subpart 5.101, which mandates public dissemination of proposed contract actions. The justification for the sole source action is based on FAR 6.103-1, which allows for noncompetitive procurement when only one responsible source is capable of fulfilling the agency’s requirements. In this instance, Abbott Laboratories, Inc. is identified as the only source able to provide the necessary analyzers and related materials compatible with the clinic’s existing systems and operational needs. The applicable North American Industry Classification System (NAICS) code for this requirement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a Small Business Administration (SBA) size standard of 1,250 employees. The Product Service Code (PSC) is 6550, covering In Vitro Diagnostic Substances, Reagents, Test Kits, and Sets. It is important to note that this notice is not a solicitation or a request for competitive proposals. No solicitation documents are available, and unsolicited offers will not be considered. However, interested parties who believe they are capable, certified, and responsible may submit a Capabilities Statement on company letterhead. Such statements must provide clear, compelling, and convincing evidence that competition would be advantageous to the Government. Submissions must be sent via email to Donna Rodriguez ([email protected]) and Mary Shifflett ([email protected]) no later than 12:00 P.M. EDT on September 2, 2026. The Government will use any responses solely to determine whether to proceed with a competitive procurement; the final decision rests at the Government’s discretion. The place of performance for this contract remains Columbia, South Carolina. The contracting activity is managed by the Defense Health Agency Contracting Activity Healthcare Contracting Division, Southeast (DHACA-HCD-SE). Contractors evaluating this opportunity should note that the procurement is a sole source action with no set-aside requirements, and is intended to ensure continuity of critical diagnostic services at a key military health facility. The long-term nature of the contract modification and the specificity of the required analyzers and materials suggest that only vendors with compatible, proven solutions and established relationships with the DHA are likely to be considered. For further information or to express interest, contractors should contact the designated DHA representatives as listed above.